Index of artpub/2021/270265/

Herbst, R.S
Five Year Survival Update From KEYNOTE-010 : Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC
2021
https://ddd.uab.cat/record/270265